|
Synonyms: CPD-231 [WO2020038415] | TR-231 [WO2020038415]
Compound class:
Synthetic organic
Comment: Sovutrecdeg is the INN for a tropomyosin receptor kinase (TRK) degrader, that was included in WHO INN Proposed List 135 (July 2026). Its chemical structure indicates that it is a cereblon (CRBN)-engaging PROTAC degrader, with an entrectinib-derived moiety to bind the target of interest. It is one of the structures claimed in patent WO2020038415A1 (Cullgen Shanghai, company acquired by Gyre Therapeutics in May 2026) [1]. The lead pan-TRK protein degrader being developed by Gyre is CG001419, and although its structure has not been formally disclosed (as of July 2026), sovutrecdeg may be the proposed INN for this clinical candidate.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT07394374 | A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities | Phase 1/Phase 2 Interventional | Cullgen (Shanghai),Inc | ||
| NCT06636500 | A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects | Phase 1 Interventional | Cullgen Inc. | ||